As first reported by Endpoints News, Xaira Therapeutics has emerged as one of the most significantly funded new entrants in the biotech sector, supported by a consortium of venture capitalists and eminent scientists. The startup has announced its mission to transform drug research and development (R&D) through the integration of artificial intelligence (AI). Marc Tessier-Lavigne, a former president of Stanford University and chief scientific officer at Genentech, has been appointed as CEO of Xaira ..read more

Rubedo Life Sciences, a biopharmaceutical company specializing in the development of therapies targeting senescent cells associated with age-related diseases, has completed a $40 million Series A financing round led by Khosla Ventures and Ahren Innovation Capital. The round saw participation from a consortium of investors, including Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, and Italian Angels for Growth (IAG), among others. Rubedo's proprietary ALEMBIC™ drug discovery platform is at the core of its operations, facilitating the identification a ..read more

We have recently launched a report, “It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?” where we gathered historical data about drug pipeline progression over the years for the select AI-driven drug discovery platforms ..read more

In an industry as critical as clinical trials, where efficient data management and swift processes are paramount, outdated tech methods often create organizational barriers. Digital tools, data management systems, and analytical dashboards are generally ways to improve clinical trial design and operational efficiency.  In fact, statistical surveys reveal tangible advancements in efficiency and technological integration within clinical trials. The rapid adoption of digital tools, including electronic Investigator Site Files (eISF) and electronic consent (eConsent), has increased marke ..read more

Kroll, a global leader in risk and financial advisory solutions, has unveiled findings from its recent "State of Cyber Defense: Diagnosing Cyber Threats in Healthcare" report. This study highlights a significant disparity between perceived and actual cybersecurity maturity within the healthcare sector. The report finds that while nearly half of the healthcare businesses surveyed consider their cybersecurity processes to be "very mature," in reality, only 3% possess truly mature cyber processes ..read more

Any given human blood sample has 15,000 small biological molecules that can give precise information about a person’s health at any given time. However, less than 5% of these molecules are known and can be identified. The team at Isospec Analytics has developed a breakthrough biomolecular analysis technology that identifies unknown molecules at scale for pharmaceutical, agritech and nutrition companies ..read more

Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and conducted several exploratory studies The last 4 years have witnessed at least twofold increase in industrial validation of organ-on-chips across various fields and organ models The majority of the studies can be broadly categorized under ADME&T (ADME & toxicity) (55.7%) followed by disease modeling on chips (30%) The rigorous industrial testing and strong backing from regulatory agencies indicate, the next 3-5 years can be a favorable inv ..read more

Seed Health has announced the launch of CODA, a cutting-edge computational biology platform that utilizes the extensive data from the Human Phenotype Project. This project, led by Professor Eran Segal from the Weizmann Institute of Science, boasts the world’s most comprehensive multi-omics data set. CODA is designed to harness this data to forge new paths in the development of precision probiotics and microbiome-directed interventions, with initial focus areas including cardiometabolic health, brain health, menopause, and longevity ..read more

My interview with Mirit Eldor, Managing Director, Life Sciences Solutions, at Elsevier, as we discuss Elsevier's recent collaboration with gen AI company Iktos and broader efforts ..read more

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success for these assets, we can uncover undervalued companies, offering a strategic edge not only to hedge funds and VCs but also to big pharma companies considering acquisitions. In this dynamic landscape, projected to see M&A activities reaching as ..read more